A lifetime versus a graft life approach redefines the importance of HLA matching in kidney transplant patients

Transplantation

Volumn 88, Issue 1, 2009, Pages 23-29

  Meier Kriesche, Herwig Ulf ^a,b   Scornik, Juan C ^b   Susskind, Brian ^c   Rehman, Shehzad ^a   Schold, Jesse D ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

HLA matching; Retransplantation; Sensitization

Indexed keywords

HLA A ANTIGEN; HLA B ANTIGEN; HLA DR ANTIGEN; PANEL REACTIVE ANTIBODY; HLA ANTIGEN;

AFRICAN AMERICAN; AGE; ARTICLE; CLINICAL ARTICLE; FEMALE; GRAFT SURVIVAL; HLA MATCHING; HLA SYSTEM; HUMAN; KIDNEY ALLOGRAFT; KIDNEY TRANSPLANTATION; LIFE EXPECTANCY; LIFESPAN; MALE; PRIORITY JOURNAL; RISK FACTOR; UNITED STATES; ADOLESCENT; ADULT; AGED; BLOOD; CHILD; COMPARATIVE STUDY; GRAFT REJECTION; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY TEST; HOSPITAL ADMISSION; IMMUNOLOGY; INFANT; MIDDLE AGED; NEWBORN; PATIENT SELECTION; PRESCHOOL CHILD; REGISTER; REGRESSION ANALYSIS; REOPERATION; RISK ASSESSMENT; STATISTICAL MODEL; TIME; TRANSPLANTATION; TRANSPLANTATION TOLERANCE;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; INFANT; INFANT, NEWBORN; KIDNEY TRANSPLANTATION; LEAST-SQUARES ANALYSIS; LIFE EXPECTANCY; LOGISTIC MODELS; MALE; MIDDLE AGED; PATIENT SELECTION; REGISTRIES; REOPERATION; RISK ASSESSMENT; TIME FACTORS; TISSUE AND ORGAN PROCUREMENT; TRANSPLANTATION TOLERANCE; UNITED STATES; WAITING LISTS; YOUNG ADULT;

EID: 67651043152     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181a9ec89     Document Type: Article

References (25)

1. Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: Have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant 2004; 4: 1289.
2. Meier-Kriesche HU, Schold JD, Srinivas TR, et al. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4: 378.
3. Roberts JP, Wolfe RA, Bragg-Gresham JL, et al. Effect of changing the priority for HLA matching on the rates and outcomes of kidney transplantation in minority groups. N Engl J Med 2004; 350: 545.
4. United Network for Organ Sharing. OPTN/UNOS board revises kidney policy to boost minority transplants. Available at: http://www.unos.org/news/ newsDetail.asp?id=228. Accessed May 27, 2009.
5. Shaughnessy M. California transplant donor network kidney variance. Available at: http://www.ctdn.org/downloads/CTDNKidneyVariance.pdf. Accessed May 27, 2009.
6. Gjertson DW, Cecka JM. Living unrelated donor kidney transplantation. Kidney Int 2000; 58: 491.
7. Meier-Kriesche HU, Ojo AO, Leichtman AB, et al. Interaction of mycophenolate mofetil and HLA matching on renal allograft survival. Transplantation 2001; 71: 398.
8. Schnitzler MA, Hollenbeak CS, Cohen DS, et al. The economic implications of HLA matching in cadaveric renal transplantation. N Engl J Med 1999; 341: 1440.
9. McCune TR, Thacker LR, Blanton JW, et al. Sensitized patients require sharing of highly matched kidneys. Transplantation 2002; 73: 1891.
10. Takemoto S, Port FK, Claas FH, et al. HLA matching for kidney transplantation. Hum Immunol 2004; 65: 1489.
11. Mizutani K. HLA mismatches and PRA in kidney retransplants. Clin Transpl 2007; 19.
12. Zachary AA, Hart JM, Lucas DP, et al. The cost of mismatching. Clin Transpl 2007; 261.
13. Park MS, Terasaki PI, Lau M, et al. Sensitization after transplantation. Clin Transpl 1987; 393.
14. Gjertson DW. A multi-factor analysis of kidney regraft outcomes. Clin Transpl 2002; 335.
15. Health Resources and Services Administration, Healthcare Systems Bureau Division of Transplantation, Rockville, MD, 2007 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients. Transplant Data 1997-2006. Available at: http://www.ustransplant.org/. Accessed on 2007.
16. Takemoto SK, Cecka JM, Terasaki PI. Benefits of HLA-CREG matching for sensitized recipients as illustrated in kidney regrafts. Transplant Proc 1997; 29: 1417.
17. Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008; 359: 242.
18. Meier-Kriesche HU, Kaplan B. Waiting time on dialysis as the strongest modifiable risk factor for renal transplant outcomes: A paired donor kidney analysis. Transplantation 2002; 74: 1377.
19. Sanfilippo F, Goeken N, Niblack G, et al. The effect of first cadaver renal transplant HLA-A, B match on sensitization levels and retransplant rates following graft failure. Transplantation 1987; 43: 240.
20. Dankers MK, Witvliet MD, Roelen DL, et al. The number of amino acid triplet differences between patient and donor is predictive for the antibody reactivity against mismatched human leukocyte antigens. Transplantation 2004; 77: 1236.
21. Gritsch HA, Veale JL, Leichtman AB, et al. Should pediatric patients wait for HLA-DR-matched renal transplants? Am J Transplant 2008; 8: 2056.
22. Scornik JC, LeFor WM, Cicciarelli JC, et al. Hyperacute and acute kidney graft rejection due to antibodies against B cells. Transplantation 1992; 54: 61.
23. Leffell MS, Cherikh WS, Land G, et al. Improved definition of human leukocyte antigen frequencies among minorities and applicability to estimates of transplant compatibility. Transplantation 2007; 83: 964.
24. Schold JD, Meier-Kriesche HU. Which renal transplant candidates should accept marginal kidneys in exchange for a shorter waiting time on dialysis? Clin J Am Soc Nephrol 2006; 1: 532.
25. Wolfe RA, McCullough KP, Schaubel DE, et al. Calculating life years from transplant (LYFT): Methods for kidney and kidney-pancreas candidates. Am J Transplant 2008; 8: 997.